GlassScriptPhysician profile
Saurabh Mangalik
NPI 1801971486
$14,217.30
in general payments reported to CMS, 2019-2025
57 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,831 · 2020: $1,631 · 2021: $1,808 · 2022: $1,810 · 2023: $3,150 · 2024: $2,385 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,038 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,037.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,096.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,799.41 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,451.18 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $914.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $767.55 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $755.97 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $629.79 | 2019-2025 | |
| Amgen INC. | $546.66 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $530.83 | 2021-2025 | |
| Allergan, INC. | $522.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $410.70 | 2019-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $395.42 | 2019-2024 | |
| Esperion Therapeutics, INC. | $376.76 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.65 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.90 | 2019-2025 | Xifaxan, Trulance |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Mangalik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.